EpiDestiny

Privately held: no public share price

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 2
DNMT1 (DNA methyltransferase 1)Small molecule
Sickle Cell Disease

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

June 2026PresentationDecitabine/Tetrahydrouridine (NDec)ASCENT1 Phase 2 (NCT05405114) results at EHA 2026: hemoglobin up 0.97 g/dL with the twice-weekly-cycle regimen

Financial reports

No financial reports recorded.